Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
* INCLUSION CRITERIA:~A volunteer must meet all of the following criteria:~1. 18 to 50 years old for Groups 1 and 2; 18 to 65 years old for Groups 3, 4, and 5.~2. Available for clinical follow-up through Week 48 after enrollment for groups 1-4 and through at least Week 4 after enrollment for group 5, with no planned travel that would preclude completion of the Study Week 4 visit.~3. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.~4. Able and willing to complete the informed consent process.~5. Willing to donate blood for sample storage to be used for future research.~6. In good general health without clinically significant medical history.~7. Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) less than or equal to 40 within the 56 days prior to enrollment.~8. For Group 3 volunteers only, must have received the VRC-EBODNA023-00-VP (Ebola DNA WT) vaccine in the VRC 206 study.~   Laboratory Criteria within 56 days prior to enrollment:~9. Hemoglobin greater than or equal to 11.5 g/dL for women; greater than or equal to 13.0 g/dL for men.~10. White blood cells (WBC) = 3,300-12,000 cells/mm(3).~11. WBC differential either within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval.~12. Total lymphocyte count greater than or equal to 800 cells/mm(3).~13. Platelets = 125,000 400,000/mm(3).~14. Alanine aminotransferase (ALT) less than or equal to 1.25 times upper limit of normal.~15. Serum creatinine less than or equal to 1 times upper limit of normal.~16. Partial thromboplastin time (PTT) within institutional normal range.~17. Prothrombin time (PT) within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval.~18. HIV-uninfected as evidenced by a negative FDA-approved HIV diagnostic blood test.~    Female-Specific Criteria:~19. Negative Beta-HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day of enrollment if woman is presumed to be of reproductive potential.~20. Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 24 weeks after study vaccination if presumed to be of reproductive potential.~EXCLUSION CRITERIA:~A volunteer will be excluded if one or more of the following conditions apply:~Volunteer has received any of the following substances:~1. Investigational Ebola or Marburg vaccine in a prior clinical trial (except for Group 3 volunteers) or prior receipt of a cAd3 adenoviral vectored investigational vaccine.~2. Immunosuppressive medications within 2 weeks prior to enrollment.~3. Blood products within 112 days (16 weeks) prior to enrollment.~4. Investigational research agents within 28 days (4 weeks) prior to enrollment.~5. Live attenuated vaccines within 28 days (4 weeks) prior to enrollment.~6. Subunit or killed vaccines within 14 days (2 weeks) prior to enrollment.~7. Current anti-tuberculosis prophylaxis or therapy.~   Female-specific criteria:~8. Woman who is breast-feeding or planning to become pregnant during the first 24 weeks after study vaccine administration.~   Volunteer has a history of any of the following clinically significant conditions:~9. Serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain.~10. Clinically significant autoimmune disease or immunodeficiency.~11. Asthma that is not well controlled.~12. Diabetes mellitus (type I or II), with the exception of gestational diabetes.~13. Thyroid disease that is not well controlled.~14. A history of hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema.~15. Idiopathic urticaria within the last 1 year.~16. Hypertension that is not well controlled.~17. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.~18. Malignancy that is active or history of a malignancy that is likely to recur during the period of the study.~19. Seizure in the past 3 years or treatment for seizure disorder in the past 3 years.~20. Asplenia or functional asplenia.~21. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within five years prior to enrollment, history of a suicide plan or attempt.~22. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): cAd3-EBO at 2x10(10)PU IM
- Group 2 (Type: EXPERIMENTAL): cAd3-EBO at 2x10(11)PU IM
- Group 3 (Type: EXPERIMENTAL): cAd3-EBO at 2x10(11)PU IM boost of Ebola DNA WT vaccine (VRC 206 participants)
- Group 4A (Type: EXPERIMENTAL): cAd3-EBOZ at 1x10(10)PU IM
- Group 4B (Type: EXPERIMENTAL): cAd3-EBOZ at 1x10(11)PU IM
- Group 5 (Type: EXPERIMENTAL): cAd3-EBO at 2x10(11)PU IM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete